Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to
evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to
severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for
8 consecutive weeks.